MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Comorbidities in Huntington’s disease: An Enroll-HD analysis

J. Mills, J. Long, J. Vaidya, C. Sampaio, S. Sathe (Iowa City, USA)

Meeting: 2022 International Congress

Abstract Number: 647

Keywords: Familial neurodegenerative diseases

Category: Huntington's Disease

Objective: Determine the frequency of comorbidities in people with Huntington’s disease (PwHD) in comparison to non-carrier controls in the Enroll-HD cohort.

Background: Despite some publications suggesting cardiac, muscle, and/or liver involvement, the impact of Huntington’s disease on organs apart from the brain is not well studied. Therapeutics that aim to lower systemic and CNS expression of both the mutant and normal HTT gene are being developed. Since the HTT protein is ubiquitously expressed, it is important to define the systemic pathology in PwHD. Observational studies such as REGISTRY [1] and Enroll-HD [2] have collected comorbidity data from thousands of PwHD and control participants worldwide.

Method: After combining REGISTRY and Enroll-HD data, we used ICD-10 codes to identify comorbidities for each system. PwHD were classified according to the Huntington’s Disease Integrated Staging System (HD-ISS) [3]. The system consists of 4 stages: Stage 0, CAG≥40; Stage 1, caudate and/or putamen atrophy; Stage 2, motor and/or cognitive signs; and Stage 3, functional change. We applied logistic regression, adjusting for age, sex, BMI, and diabetes, to examine the presence of each condition for HD-ISS stages versus controls. Specifically, we examined the occurrence of infectious disease and cancer as well as endocrine, neurological, cardiovascular, pulmonary, gastrointestinal, musculoskeletal, and genitourinary disorders.

Results: 13,845 PwHD participants (75.2%; mean age 47.7 years, 54% F) and 4559 controls (24.8%; 46.6 years, 62% F) collectively reported 24,551 comorbidities. Sleep disorders, falls, and orthopedic complications are more frequent in PwHD compared to controls. Several conditions appear to have slightly higher frequency for PwHD, including infectious disease and disorders of the pulmonary, gastrointestinal, and genitourinary systems. Some conditions appear less frequently for certain HD-ISS Stages versus controls, notably diabetes (Stage 1) and hypertension (Stage 1-3). [table1]

Conclusion: In contrast to previous reports, our analysis suggests that the frequency of systemic comorbidities is largely similar between PwHD and controls. Further exploration of specific comorbidities such as sleep disorders is warranted. Delineation of systemic comorbidities will help interpret investigational drug-related adverse events. A version of this abstract was accepted as a poster presentation at HDTC, Palm Springs, CA, February 28-March 3, 2022.

MDS Abstract Table

References: 1. Orth M, Handley OJ, Schwenke C, Landwehrmeyer B. Observing Huntington’s disease: the European Huntington’s disease network’s REGISTRY. Journal of Neurology, Neurosurgery, and Psychiatry. 2010;82:1409–12.
2. Landwehrmeyer BG, Fitter-Attas C, Giuliano J, et al. Data analytics from Enroll-HD, a global clinical research platform for Huntington’s disease. Movement Disorder Clinical Practice. 2016;4:212–24.
3. Tabrizi SJ, Schobel SA, Gantman EC, et al. Huntington’s Disease Integrated Staging System (HD-ISS): A Novel Evidence-Based Classification System For Staging. Lancet Neurology. 2021.

To cite this abstract in AMA style:

J. Mills, J. Long, J. Vaidya, C. Sampaio, S. Sathe. Comorbidities in Huntington’s disease: An Enroll-HD analysis [abstract]. Mov Disord. 2022; 37 (suppl 2). https://www.mdsabstracts.org/abstract/comorbidities-in-huntingtons-disease-an-enroll-hd-analysis/. Accessed July 11, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2022 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/comorbidities-in-huntingtons-disease-an-enroll-hd-analysis/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • An atypical and interesting feature of Parkinson´s disease
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley